LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Leishmania major adenylate kinase immunization offers partial protection to a susceptible host

Photo by cdc from unsplash

Leishmania major causes mild‐to‐severe cutaneous lesions resulting in significant disfigurations, if untreated. The drugs are toxic, and drug‐resistance parasites are emerging. Therefore, a prophylactic vaccination is an urgent need. As… Click to show full abstract

Leishmania major causes mild‐to‐severe cutaneous lesions resulting in significant disfigurations, if untreated. The drugs are toxic, and drug‐resistance parasites are emerging. Therefore, a prophylactic vaccination is an urgent need. As no vaccine is available, we compared the genes expressed by virulent and avirulent parasites. We identify L major adenylate kinase (AdeK) as a probable vaccine candidate after a series of experimentations. We cloned the gene in mammalian pcDNA6/HisA and pet28a+ vector for in vivo expression following immunization and in vitro protein expression for booster, respectively. We observed that immunization of susceptible BALB/c mice with AdeK resulted in significant protection against L major challenge infection. The protection was accompanied by increased IFN‐γ producing lymphocytes and reduced IL‐4, IL‐17 and IL‐10 secreting central and effector Th2, Th17 and Treg memory cells, respectively. These observations indicate L major AdeK as a potential vaccine candidate.

Keywords: protection; immunization; leishmania major; major adenylate; adenylate kinase

Journal Title: Parasite Immunology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.